Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Researchers identify class of drugs that can promote RBC formation in anemic patients

Researchers identify class of drugs that can promote RBC formation in anemic patients

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Researchers show how malaria parasites infect red blood cells, impede blood flow to organs

Researchers show how malaria parasites infect red blood cells, impede blood flow to organs

Whitehead Institute Founding Member named recipient of 2011 Warren Triennial Prize of MGH

Whitehead Institute Founding Member named recipient of 2011 Warren Triennial Prize of MGH

Study: Natural high hemoglobin levels safe for kidney disease patients on dialysis

Study: Natural high hemoglobin levels safe for kidney disease patients on dialysis

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Medication and blood transfusion reduce risk of recurrent strokes in young patients with sickle cell anemia

Medication and blood transfusion reduce risk of recurrent strokes in young patients with sickle cell anemia

Mayo Clinic scientists say JAK inhibitors may help treat patients with myelofibrosis

Mayo Clinic scientists say JAK inhibitors may help treat patients with myelofibrosis

Positive interim data from Phase I/II trial of CYT387 in myelofibrosis presented at ASH Annual Meeting

Positive interim data from Phase I/II trial of CYT387 in myelofibrosis presented at ASH Annual Meeting

New drug appears to help patients with chronic myeloid leukemia

New drug appears to help patients with chronic myeloid leukemia

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

New analysis evaluates association between hemolysis, mortality in patients with PNH

New analysis evaluates association between hemolysis, mortality in patients with PNH

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.